CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D, discussing CytoDyn’s PRO140 monoclonal antibody therapy for HIV and cancer.
The company is at a key inflection point, with potential FDA approval for PRO140 for treating HIV expected in 2019.
Dr. Pourhassan explains the PRO140 technology, its numerous advantages over current HIV therapies on the market, market potential, as well as expanding PRO140’s indications for treating cancer.
Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Comments (0)